Deutsche Bank sets Sarepta stock target at $136, cites risks
Deutsche Bank (ETR:DBKGn) initiated coverage of Sarepta Therapeutics (NASDAQ:SRPT), assigning a Hold rating to the ...
Goldman Sachs cuts Regenxbio stock rating, slashes price target
Goldman Sachs made a significant adjustment to its stance on Regenxbio Inc . (NASDAQ:RGNX), downgrading the stock from "Buy" to "Neutral" and reducing the price target dramatically to $14.00 from the ...
Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns
Regenxbio's gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and ...
Sarepta initiated with a Hold at Deutsche Bank
Deutsche Bank analyst David Hoang initiated coverage of Sarepta (SRPT) with a Hold rating and $136 price target Maximize Your Portfolio with ...
EuropaWire11h
Patients as Partners® Europe Launches the 9th Annual Event with 2025 Keynotes, Featured Speakers and Topics
The Conference Forum has announced the 9th annual Patients as Partners® Europe event, scheduled for May 20-21, 2025, at the Royal National Hotel ...